Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission Correction

<sup>18</sup>F-FDG Positron Emission Tomography (PET) is used to monitor tumor response to <sup>131</sup>I-therapy, but is confounded by prompt emissions (284, 364, 637, and 723 keV) from <sup>131</sup>I, particularly in animal PET imaging. We propose a method for...

Full description

Bibliographic Details
Main Authors: Young Sub Lee, Hee-Joung Kim, Jin Su Kim
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/9/4/144
_version_ 1811298273454981120
author Young Sub Lee
Hee-Joung Kim
Jin Su Kim
author_facet Young Sub Lee
Hee-Joung Kim
Jin Su Kim
author_sort Young Sub Lee
collection DOAJ
description <sup>18</sup>F-FDG Positron Emission Tomography (PET) is used to monitor tumor response to <sup>131</sup>I-therapy, but is confounded by prompt emissions (284, 364, 637, and 723 keV) from <sup>131</sup>I, particularly in animal PET imaging. We propose a method for correcting this emission in <sup>18</sup>F-FDG PET. The <sup>131</sup>I prompt emission effect was assessed within various energy windows and various activities. We applied a single gamma correction method to a phantom and in vivo mouse model. The <sup>131</sup>I prompt emission fraction was 12% when 300 &#181;Ci of <sup>131</sup>I and 100 &#181;Ci of FDG were administered, and increased exponentially with escalating <sup>131</sup>I activity for all energy windows. The difference in spill-over ratio was reduced to &lt;5% after <sup>131</sup>I prompt emission correction. In the mouse model, the standard uptake value (SUV) did not differ significantly between FDG PET only (gold standard) and FDG PET after <sup>131</sup>I prompt emission-correction, whereas it was overestimated by 38% before correction. Contrast was improved by 18% after <sup>131</sup>I prompt emission correction. We first found that count contamination on <sup>18</sup>F-FDG follow-up scans due to <sup>131</sup>I spilled-over count after <sup>131</sup>I rituximab tumor targeted therapy. Our developed <sup>131</sup>I prompt emission-correction method increased accuracy during measurement of standard uptake values on <sup>18</sup>F-FDG PET.
first_indexed 2024-04-13T06:17:02Z
format Article
id doaj.art-23d10db558204f1e9ccaf6b1cdeeea54
institution Directory Open Access Journal
issn 2075-4418
language English
last_indexed 2024-04-13T06:17:02Z
publishDate 2019-10-01
publisher MDPI AG
record_format Article
series Diagnostics
spelling doaj.art-23d10db558204f1e9ccaf6b1cdeeea542022-12-22T02:58:47ZengMDPI AGDiagnostics2075-44182019-10-019414410.3390/diagnostics9040144diagnostics9040144Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission CorrectionYoung Sub Lee0Hee-Joung Kim1Jin Su Kim2Division of RI Application, Korea Institute Radiological and Medical Sciences, Seoul 01812, KoreaDepartment of Radiation Convergence Engineering and Research Institute of Health Science, Yonsei University, Wonju 26493, KoreaDivision of RI Application, Korea Institute Radiological and Medical Sciences, Seoul 01812, Korea<sup>18</sup>F-FDG Positron Emission Tomography (PET) is used to monitor tumor response to <sup>131</sup>I-therapy, but is confounded by prompt emissions (284, 364, 637, and 723 keV) from <sup>131</sup>I, particularly in animal PET imaging. We propose a method for correcting this emission in <sup>18</sup>F-FDG PET. The <sup>131</sup>I prompt emission effect was assessed within various energy windows and various activities. We applied a single gamma correction method to a phantom and in vivo mouse model. The <sup>131</sup>I prompt emission fraction was 12% when 300 &#181;Ci of <sup>131</sup>I and 100 &#181;Ci of FDG were administered, and increased exponentially with escalating <sup>131</sup>I activity for all energy windows. The difference in spill-over ratio was reduced to &lt;5% after <sup>131</sup>I prompt emission correction. In the mouse model, the standard uptake value (SUV) did not differ significantly between FDG PET only (gold standard) and FDG PET after <sup>131</sup>I prompt emission-correction, whereas it was overestimated by 38% before correction. Contrast was improved by 18% after <sup>131</sup>I prompt emission correction. We first found that count contamination on <sup>18</sup>F-FDG follow-up scans due to <sup>131</sup>I spilled-over count after <sup>131</sup>I rituximab tumor targeted therapy. Our developed <sup>131</sup>I prompt emission-correction method increased accuracy during measurement of standard uptake values on <sup>18</sup>F-FDG PET.https://www.mdpi.com/2075-4418/9/4/144<sup>18</sup>f-fdg petpersonalized medicine<sup>131</sup>i prompt emission-correctionradioimmunotherapyrituximabrituxan
spellingShingle Young Sub Lee
Hee-Joung Kim
Jin Su Kim
Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission Correction
Diagnostics
<sup>18</sup>f-fdg pet
personalized medicine
<sup>131</sup>i prompt emission-correction
radioimmunotherapy
rituximab
rituxan
title Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission Correction
title_full Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission Correction
title_fullStr Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission Correction
title_full_unstemmed Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission Correction
title_short Improved Quantification of <sup>18</sup>F-FDG PET during <sup>131</sup>I-Rituximab Therapy on Mouse Lymphoma Models after <sup>131</sup>I Prompt Emission Correction
title_sort improved quantification of sup 18 sup f fdg pet during sup 131 sup i rituximab therapy on mouse lymphoma models after sup 131 sup i prompt emission correction
topic <sup>18</sup>f-fdg pet
personalized medicine
<sup>131</sup>i prompt emission-correction
radioimmunotherapy
rituximab
rituxan
url https://www.mdpi.com/2075-4418/9/4/144
work_keys_str_mv AT youngsublee improvedquantificationofsup18supffdgpetduringsup131supirituximabtherapyonmouselymphomamodelsaftersup131supipromptemissioncorrection
AT heejoungkim improvedquantificationofsup18supffdgpetduringsup131supirituximabtherapyonmouselymphomamodelsaftersup131supipromptemissioncorrection
AT jinsukim improvedquantificationofsup18supffdgpetduringsup131supirituximabtherapyonmouselymphomamodelsaftersup131supipromptemissioncorrection